Turna Ray

A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.

The pandemic increased interest in virtual, tech-enabled enrollment strategies, but pharma wants to see if early studies succeed before jumping in.

Researchers are using recently awarded grants to improve detection of FGFR fusions using liquid biopsy and their understanding of "blood kinetics" on therapy.

The company plans to launch a polygenic risk score, a germline-somatic test platform, and LDT and kitted tests for disease monitoring and therapy selection.

A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.

National Government Services' proposal to broaden coverage of large sequencing panels for solid tumor patients is positive but may need clarification to ensure appropriate patient care.

The EC has stuck with its timeline to implement the new regulations in eight months, raising concerns for cancer patients' ability to receive biomarker testing and treatments.

A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.

Updated results from IMpower010 showed NSCLC patients with PD-L1 expression in 1 to 49 percent of tumor cells derived less benefit from adjuvant Tecentriq than those with higher expression.

The study presented at the ESMO Congress also suggested that ctDNA testing may predict which patients should have surgery to remove their tumors and those who can do without it.